The power of ten in HIV remission: insights from hematopoietic stem cell transplantation.

IF 4
Current opinion in HIV and AIDS Pub Date : 2025-09-01 Epub Date: 2025-07-09 DOI:10.1097/COH.0000000000000954
Javier Martinez-Picado, Mi Kwon, Maria Salgado
{"title":"The power of ten in HIV remission: insights from hematopoietic stem cell transplantation.","authors":"Javier Martinez-Picado, Mi Kwon, Maria Salgado","doi":"10.1097/COH.0000000000000954","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>This review discusses emerging insights from ten cases of HIV remission following allogeneic hematopoietic stem cell transplantation (allo-HSCT). With more than 40 million people living with HIV and current therapies offering lifelong control but not cure, these rare cases of viral remission provide timely and valuable perspectives for designing curative strategies.</p><p><strong>Recent findings: </strong>The review synthesizes clinical experiences from cases such as the Berlin, London, Düsseldorf, City of Hope, and New York patients. These cases have demonstrated that that the achievement of full donor chimerism and the presence of the CCR5Δ32 mutation significantly enhance the likelihood of HIV remission. However, recent evidence, including the Geneva patient, shows that remission may also occur without the mutation, suggesting a pivotal role for alloreactivity in clearing viral reservoirs. Studies also highlight virological, hematological, and immunological markers that are critical for monitoring remission and informing safe interruption of antiretroviral therapy.</p><p><strong>Summary: </strong>Although allo-HSCT is not scalable for all persons living with HIV due to its risks and complexity, the ten cases of remission addressed here have deepened our understanding of HIV persistence and eradication mechanisms. The insights gained may guide the development of more accessible and safer cure strategies in the future.</p>","PeriodicalId":93966,"journal":{"name":"Current opinion in HIV and AIDS","volume":" ","pages":"456-462"},"PeriodicalIF":4.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337928/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in HIV and AIDS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/COH.0000000000000954","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: This review discusses emerging insights from ten cases of HIV remission following allogeneic hematopoietic stem cell transplantation (allo-HSCT). With more than 40 million people living with HIV and current therapies offering lifelong control but not cure, these rare cases of viral remission provide timely and valuable perspectives for designing curative strategies.

Recent findings: The review synthesizes clinical experiences from cases such as the Berlin, London, Düsseldorf, City of Hope, and New York patients. These cases have demonstrated that that the achievement of full donor chimerism and the presence of the CCR5Δ32 mutation significantly enhance the likelihood of HIV remission. However, recent evidence, including the Geneva patient, shows that remission may also occur without the mutation, suggesting a pivotal role for alloreactivity in clearing viral reservoirs. Studies also highlight virological, hematological, and immunological markers that are critical for monitoring remission and informing safe interruption of antiretroviral therapy.

Summary: Although allo-HSCT is not scalable for all persons living with HIV due to its risks and complexity, the ten cases of remission addressed here have deepened our understanding of HIV persistence and eradication mechanisms. The insights gained may guide the development of more accessible and safer cure strategies in the future.

Abstract Image

Abstract Image

Abstract Image

艾滋病缓解的力量:来自造血干细胞移植的见解。
综述目的:本综述讨论了10例同种异体造血干细胞移植(alloo - hsct)后HIV缓解的新见解。由于有4000多万艾滋病毒感染者,目前的治疗方法只能终生控制,但不能治愈,这些罕见的病毒缓解病例为设计治疗策略提供了及时和有价值的视角。最新发现:该综述综合了来自柏林、伦敦、塞尔多夫、希望之城和纽约等病例的临床经验。这些病例表明,实现完全供体嵌合和CCR5Δ32突变的存在显着提高了HIV缓解的可能性。然而,最近的证据,包括日内瓦病人在内,表明没有突变也可能出现缓解,这表明同种异体反应在清除病毒库中起着关键作用。研究还强调了病毒学、血液学和免疫学标记物对监测缓解和告知安全中断抗逆转录病毒治疗至关重要。摘要:尽管由于其风险和复杂性,同种异体造血干细胞移植并不适用于所有HIV感染者,但本文讨论的10例缓解病例加深了我们对HIV持续存在和根除机制的理解。所获得的见解可能会指导未来更容易获得和更安全的治疗策略的发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信